The recent success of the fusion inhibitor T-20 (enfuvirtide) in clinical studies has ushered in
a new chapter in the development of anti-HIV-1 therapeutics. T-20 is the first FDA-approved …

Elicitation of antibodies against targets that are immunorecessive, cryptic, or transient in their
native context has been a challenge for vaccine design. Here we demonstrate the elicitation …

The membrane-proximal region of the ectodomain of the gp41 envelope glycoprotein of
human immunodeficiency virus type 1 (HIV-1) is the target of three of the five broadly …

Induction of effective antibody responses against HIV-1 infection remains an elusive goal for
vaccine development. Progress may require in-depth understanding of the molecular …

The conserved membrane-proximal external region (MPER) of human immunodeficiency
virus type 1 (HIV-1) gp41 is a target of two broadly neutralizing human monoclonal …

Peptides derived from the heptad repeat 2 (HR2) region of the HIV fusogenic protein gp41
are potent inhibitors of viral infection, and one of them, enfuvirtide, is used for the treatment …

Human immunodeficiency virus type 1 (HIV-1), the pathogen of acquired immunodeficiency
syndrome (AIDS), causes∼ 2 millions death every year and still defies an effective vaccine …

Structural properties of over 55 small proteins have been determined using both density-
based and wave-function-based electronic structure methods in order to assess the ability of …

In vitro evolution methods are now being routinely used to identify protein variants with novel
and enhanced properties that are difficult to achieve using rational design. However, one of …

Inhibition of human immunodeficiency virus (HIV) fusion with the host cell has emerged as a
viable therapeutic strategy, and rational design of inhibitors and vaccines, interfering with …